Research Analysts Set Expectations for Geron Q3 Earnings

Geron Corporation (NASDAQ:GERN) – Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for shares of Geron in a research report issued on Wednesday, May 6th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Geron’s current full-year earnings is ($0.04) per share. HC Wainwright also issued estimates for Geron’s FY2027 earnings at $0.05 EPS, FY2028 earnings at $0.16 EPS, FY2029 earnings at $0.35 EPS and FY2030 earnings at $0.59 EPS.

Several other equities research analysts have also weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Geron in a report on Monday, April 27th. TD Cowen reiterated a “buy” rating on shares of Geron in a report on Thursday, January 29th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $2.50.

Geron Stock Performance

GERN opened at $1.46 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.62 and a current ratio of 4.66. The company has a market cap of $935.71 million, a PE ratio of -13.27 and a beta of 0.68. The stock has a 50-day moving average of $1.59 and a 200-day moving average of $1.43. Geron has a 52-week low of $1.04 and a 52-week high of $2.01.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. Geron had a negative net margin of 35.48% and a negative return on equity of 22.94%. The firm had revenue of $51.84 million for the quarter, compared to the consensus estimate of $50.59 million.

Institutional Trading of Geron

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. 55 North Private Wealth LLC acquired a new position in Geron in the 4th quarter valued at approximately $29,000. LCM Capital Management Inc boosted its holdings in Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC bought a new stake in shares of Geron in the 4th quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new stake in shares of Geron in the 1st quarter valued at approximately $33,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Geron by 3,307.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 24,410 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.